OS Therapies Incorporated Total Liabilities
OS Therapies Incorporated total liabilities. Based on the latest financial reports, OS Therapies Incorporated (OSTX) has total liabilities worth $4.25 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See OS Therapies Incorporated defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Total Liabilities of OS Therapies Incorporated (2020–2024)
Total liabilities of OS Therapies Incorporated from 2020 to 2024. This chart illustrates how OS Therapies Incorporated's total liabilities have evolved over time, based on quarterly financial data.
OS Therapies Incorporated Competitors by Total Liabilities
The table below lists competitors of OS Therapies Incorporated ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rigolleau SA
BA:RIGO
|
Argentina | AR$45.20 Billion |
|
DESWELL INDS INC. DL-01
F:DW2
|
Germany | €20.17 Million |
|
JSS Real Estate SOCIMI SA
MC:YJSS
|
Spain | €291.53 Million |
|
Oceanpal Inc
NASDAQ:OP
|
USA | $4.10 Million |
|
Adaptimmune Therapeutics plc
F:473A
|
Germany | €201.59 Million |
|
Elron Electronic Industries Ltd
TA:ELRN
|
Israel | ILA13.15 Million |
|
EstechPharma Co. Ltd
KQ:041910
|
Korea | ₩60.00 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down OS Therapies Incorporated's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see OSTX total assets.
Liquidity & Leverage Metrics
OS Therapies Incorporated Total Liabilities Ratios Explained
OS Therapies Incorporated total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OS Therapies Incorporated's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OS Therapies Incorporated (2020–2024)
The table below shows the annual total liabilities of OS Therapies Incorporated from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.73 Million | -80.95% |
| 2023-12-31 | $24.81 Million | +37.35% |
| 2022-12-31 | $18.07 Million | +53.40% |
| 2021-12-31 | $11.78 Million | -99.85% |
| 2020-12-31 | $8.00 Billion | -- |
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide lin… Read more